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Hypoxia is a major cause of pulmonary hypertension. Gene expression activated by the
transcriptionfactorhypoxia-induciblefactor(HIF)iscentraltothisprocess.Theoxygen-sensing
iron-dependent dioxygenase enzymes that regulate HIF are highly sensitive to varying iron
availability. It is unknown whether iron similarly inﬂuences the pulmonary vasculature. This
humanphysiologystudyaimedtodeterminewhethervaryingironavailabilityaffectspulmonary
arterial pressure and the pulmonary vascular response to hypoxia, as predicted biochemically
by the role of HIF. In a controlled crossover study, 16 healthy iron-replete volunteers
undertook two separate protocols. The ‘Iron Protocol’ studied the effects of an intravenous
infusion of iron on the pulmonary vascular response to 8h of sustained hypoxia. The
‘Desferrioxamine Protocol’ examined the effects of an 8h intravenous infusion of the iron
chelator desferrioxamine on the pulmonary circulation. Primary outcome measures were
pulmonary artery systolic pressure (PASP) and the PASP response to acute hypoxia ( PASP),
assessed by Doppler echocardiography. In the Iron Protocol, infusion of iron abolished or
greatly reduced both the elevation in baseline PASP (P<0.001) and the enhanced sensitivity
of the pulmonary vasculature to acute hypoxia (P=0.002) that are induced by exposure to
sustained hypoxia. In the Desferrioxamine Protocol, desferrioxamine signiﬁcantly elevated
both PASP (P<0.001) and  PASP (P=0.01). We conclude that iron availability modiﬁes
pulmonary arterial pressure and pulmonary vascular responses to hypoxia. Further research
should investigate the potential for therapeutic manipulation of iron status in the management
of hypoxic pulmonary hypertensive disease.
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Pulmonary hypertensive disorders frequently complicate
hypoxiclungdiseaseandworsenpatientsurvival(Barbera
et al. 2003; Chaouat et al. 2005; McLaughlin & McGoon,
2006). For example, up to 90% of patients with advanced
chronic obstructive pulmonary disease (COPD) have
moderate to severe pulmonary hypertension that worsens
survival despite maximal therapy (Oswald-Mammosser
etal.1995;Scharfetal.2002;Mal,2007).Hypoxia-induced
pulmonaryhypertensionisalsoamajorcauseofmorbidity
among high altitude residents, while in non-residents it
directly precipitates high altitude pulmonary oedema, the
most common cause of death related to high altitude
(Hackett & Roach, 2001; Penaloza & Arias-Stella, 2007).
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Hypoxia causes pulmonary hypertension through hypo-
xic pulmonaryvasoconstrictionand vascular remodelling
(Barbera et al. 2003). It has recently become apparent
that these processes are regulated at least in part by the
hypoxia-inducible factor (HIF) family of transcription
factors, which coordinate intracellular responses to
hypoxia by directly or indirectly regulating the expression
of several hundred genes (Semenza, 2004; Smith et al.
2008). In mice, heterozygous deﬁciency for functional
HIF genes markedly inhibits the development of
hypoxia-induced pulmonary hypertension and vascular
remodelling (Yu et al. 1999; Brusselmans et al. 2003),
and impairs hypoxic responses in the pulmonary arterial
myocytes responsible for these processes (Shimoda et al.
2001).Inpatientsdiagnosedwiththerarerecessivedisease
Chuvash polycythaemia, HIF-mediated gene activation is
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pathologicallyincreasedandisassociatedwithpulmonary
hypertension (Bushuev et al. 2006; Smith et al. 2006)
and a grossly exaggerated pulmonary vasoconstrictive
response to hypoxia (Smith et al. 2006). Other rare
HIF-activating mutations have also been linked to the
development of pulmonary hypertension (Gale et al.
2008).
HIF is synthesized continuously and is primarily
regulated through oxygen-dependent proteosomal
degradation. HIF is targeted for proteolysis by hydro-
xylation of speciﬁc residues in the HIF-α subunit
(Ivan et al. 2001; Jaakkola et al. 2001). This crucial
oxygen-sensitive step is catalysed by HIF
hydroxylase enzymes belonging to the iron- and
2-oxoglutarate-dependent dioxygenase superfamily, and
requires iron as an obligate cofactor. In cultured cells
HIF degradation is both inhibited by iron chelation
with desferrioxamine (DFO) and potentiated by supra-
physiological iron supplementation (Wang & Semenza,
1993; Knowles et al. 2003), raising the question of what
effectvariationsinironavailabilityhaveonHIF-signalling
at the systemic level. Previous studies in humans have
demonstrated that DFO stimulates production of the
HIF-regulated hormone erythropoietin (Ren et al. 2000)
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Figure 1. Schematic representation of experimental protocols
Each protocol was conducted over two separate days. For the Iron Protocol, a control infusion of normal saline was
administered on the ﬁrst experimental day and an infusion of iron sucrose was given on the second experimental
day. For the DFO Protocol, a control infusion of normal saline was administered on one experimental day and
an infusion of desferrioxamine (DFO) was given on the other experimental day. Pulmonary artery pressure was
assessed echocardiographically during the acute hypoxic challenges. PETO2 denotes end-tidal partial pressure of
oxygen.
andmildlyelevatespulmonaryarterialpressures(Balanos
et al. 2002).
The known biochemistry of HIF regulation and its
involvement in pulmonary physiology together suggest
that clinical iron status may modify the effects of
hypoxiaonthepulmonarycirculation.Suchaninteraction
would have important implications for patients with
hypoxia-induced pulmonary hypertension. This study
of healthy iron-replete individuals aimed to determine
the effects of increasing and decreasing iron availability
on the pulmonary vasculature and its response to
hypoxia.Theprimaryoutcomemeasureswerepulmonary
artery systolic pressure (PASP) and the change in PASP
stimulated by exposure to acute hypoxia ( PASP),
assessed by Doppler echocardiography.
Methods
Thereweretwoprotocolstothestudy ,whichareillustrated
schematically in Fig. 1. The Iron Protocol compared
the effects of intravenous iron with those of a control
infusion on the subsequent responses to 8h of sustained
hypoxia. This protocol tested the hypothesis that
increasing iron availability would attenuate the increases
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in PASP and  PASP that normally accompany sustained
exposure to hypoxia. The DFO Protocol investigated
the effect of reducing iron availability on PASP and
 PASP, by comparing the effects of an 8h intravenous
infusion of DFO with those of a control infusion. Sixteen
healthy volunteers with normal iron status participated
in the study (age 25±3year, mean± S.D.; four men
and four women in each protocol). Participants were
taking no medications or supplements, and provided
written informed consent. The Oxfordshire Clinical
ResearchEthicsCommitteeapprovedthestudy,whichwas
conductedin accordancewiththe Declarationof Helsinki.
Iron Protocol
Each participant was studied twice with the studies
separatedbyatleast1week.Theﬁrstprotocolbeganwitha
control infusion of normal saline. Following the infusion,
PASP and  PASPweremeasuredduringanacutehypoxic
challenge. Subjects were then exposed to 8h of sustained
isocapnic hypoxia (end-tidal partial pressure of oxygen,
PETO2, of 55mmHg) in a purpose built hypoxia chamber
(Howard et al. 1995). After the 8h exposure, PASP and
 PASP were again determined during an acute hypoxic
challenge. The second protocol began with an infusion
of iron(III)-hydroxide sucrose (200mg over 105min;
Syner-Med (Pharmaceutical Products) Ltd, Purley, UK)
and was otherwise identical to the ﬁrst protocol.
The order of the saline and iron infusions was not
randomised between protocols as the duration of the
potential downstream effects of iron administration is
unknown. The plasma half-life of iron sucrose is 5–6h
(Danielson et al. 1996) and the immediately bioavailable
labile iron fraction is approximately 5% (Van Wyck et al.
2004).
DFO Protocol
Each participant was studied on two days separated by
at least 1week. Participants received an 8h infusion of
desferrioxamine mesylate (4g per 70kg body weight;
Ciba-Geigy, Cheshire, UK) on one experimental day and
a control infusion of normal saline on the other. The
infusion order was randomised. PASP and  PASP were
measured during an acute hypoxic challenge before and
after the 8h infusions.
Acute hypoxic challenges: measurement of PASP
Plasma erythropoietin concentration was measured
immediately prior to each acute hypoxic challenge. The
apparatus and techniques used in the acute hypoxic
challenges have been extensively validated and described
in detail previously (Balanos et al. 2005; Smith et al.
Table 1. Baseline venous blood analyses
Analysis (normal range) DFO Protocol Iron Protocol
Haemoglobin (12–17 g dl−1) 14.0 ± 1.0 14.0 ± 1.5
Haematocrit (0.36–0.50 l l−1)0 . 4 2 ± 0.03 0.42 ± 0.04
Serum iron (11–31 μmol l−1) 21.9 ± 10.1 16.1 ± 5.6
Serum ferritin (10–300 μgl −1) 29.3 ± 14.6 72.7 ± 81.6
Mean ± S.D. values are shown. Where normal ranges vary with
sex, the widest range is given.
2006). Challenges were conducted with the subject
reclining in the left lateral position and breathing
through a mouthpiece. Gas control was achieved by
means of dynamic end-tidal forcing (Robbins et al.
1982). For each challenge an initial 5min of euoxia
(PETO2 of 100mmHg) preceded a period of 20min of
isocapnic hypoxia (PETO2 50mmHg). This was followed
by a ﬁnal 10min of euoxia. End-tidal partial pressure
of carbon dioxide was maintained close to each
subject’s baseline value. A Sonos 5500 echocardiography
machine(2–4MHz transducer;Hewlett-Packard, Boston,
MA, USA) was used to monitor PASP continuously.
Using a standard Doppler technique, the maximum
systolic pressure gradient across the tricuspid valve was
determined and PASP was calculated using the modiﬁed
Bernoulli equation and an estimated right atrial pressure
of5mmHg(Swensonetal.2002;Smithetal.2006).Heart
rateandventilationwererecorded,andcardiacoutputwas
determined echocardiographically every 2min (Howson
et al. 1986; Balanos et al. 2005).
Statistical analyses
Differences between experiment days were assessed
statisticallyusingStudent’spairedt test(MicrosoftExcel),
and were considered signiﬁcant at the P<0.05 level.
All values are expressed as means± S.D. unless otherwise
stated.
Results
All subjects were initially iron-replete (see Table 1).
All infusions were well tolerated. Neither iron nor
DFO signiﬁcantly affected ventilation, heart rate or
cardiac output, either during euoxia or in response to
hypoxia.
Iron Protocol
Figure2 shows that, of itself, infusion with iron did
not affect PASP or  PASP. However, pretreatment with
iron prevented the rise in PASP normally induced
by 8h of sustained hypoxia (increase in PASP of
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23%±13% with saline control versus 2%±3% with
iron, P<0.001). Iron also substantially attenuated the
increase in  PASP normally induced by sustained
hypoxia (increase of 124%±77% with saline control
versus increase of 59%±67% with iron, P=0.002).
Theinitialplasmaerythropoietinconcentrationmeasured
prior to the infusions was not signiﬁcantly different
on the two experimental days (13.2±1.4mIUml−1
prior to control infusion and 13.3±0.4mIUml−1 prior
to iron infusion; P=0.91). The elevation in plasma
erythropoietin concentration generated by hypoxia was
not signiﬁcantly affected by iron (increase of 67%±35%
with saline control versus increase of 61%±40% with
iron, P=0.79).
Figure 2. Effects of 8 h of sustained hypoxia on pulmonary artery systolic pressure with and without
prior infusion of iron
Upper panels show end-tidal partial pressures of oxygen (PETO2) and carbon dioxide (PETCO2) during acute hypoxic
challenges. Lower panels show corresponding measurements of pulmonary artery systolic pressure (PASP). Values
are means and error bars indicate S.E.M. The control measurements demonstrate the normal pulmonary vascular
response to sustained hypoxia, consisting of an increase in PASP and a sensitized PASP response to subsequent
acute hypoxia ( PASP). Intravenous infusion of iron prior to the 8 h hypoxic exposure prevented the increase in
b a s e l i n eP A S P( P < 0.001) and markedly attenuated the degree to which  PASP was sensitized (P = 0.002).
DFO Protocol
Figure3 shows that an 8h infusion of DFO signiﬁcantly
increased basal PASP (increase of 0%±3% with
saline control versus increase of 10%±4% with DFO,
P<0.001). DFO also increased pulmonary vascular
reactivity to acute hypoxia (1%±12% reduction in
 PASP with saline control versus 36%±26% increase
with DFO, P=0.01). The initial plasma erythropoietin
concentration measured prior to the infusions was not
signiﬁcantly different on the two experimental days
(10.4±5.8mIUml−1 prior to control infusion and
8.3±4.2mIUml−1 prior to DFO infusion; P=0.14).
DFO generated a signiﬁcant rise in plasma erythropoietin
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(control increase of 2%±65% versus increase of
794%±566% with DFO, P=0.03).
Discussion
This study establishes the existence of a novel and
substantial interaction between iron, hypoxia and the
pulmonary circulation. We are not aware of any previous
work describing such a link in animals or humans.
The results from the Iron Protocol demonstrate that, in
iron-replete individuals, administration of iron abolishes
the elevation in pulmonary arterial pressure that is
normally induced following an 8h exposure to hypo-
xia, and markedly inhibits the accompanying increase in
acute hypoxic pulmonary vasoreactivity. This introduces
the potential for beneﬁt from iron therapy in disorders
caused by pulmonary vasoconstrictive responses to hypo-
xia, such as COPD-related pulmonary hypertension and
high altitude pulmonary oedema (HAPE).
Figure 3. Effects of an 8 h infusion of desferrioxamine on pulmonary artery systolic pressure
Upper panels show end-tidal partial pressures of oxygen (PETO2) and carbon dioxide (PETCO2) during acute hypoxic
challenges. Lower panels show corresponding measurements of pulmonary artery systolic pressure (PASP). DFO
denotesdesferrioxamine.Valuesaremeansanderrorbarsindicate S.E.M.InfusionofDFOincreasedPASP(P < 0.001)
and sensitized the pulmonary vascular response to acute hypoxia (P = 0.01).
The results from the DFO Protocol demonstrate that,
for a given level of hypoxia, acute reduction of iron
availability increases pulmonary arterial pressure. This
raises the possibility that clinical iron deﬁciency might
exacerbate hypoxically induced pulmonary hypertension,
for example in cor pulmonale. Indeed, this might explain
why the initial pulmonary antihypertensive beneﬁts of
venesection for secondary polycythaemia tend not to be
sustained with continued venesection (Lewis et al. 1952;
Hecht et al. 1955; Rakita et al. 1965; Segel & Bishop, 1966;
Weisse et al. 1975).
Overall this study demonstrates the importance of
iron in pulmonary vascular responses to hypoxia and
suggests that even modest alterations in iron balance
might be clinically signiﬁcant in this respect. Although
prolonged administration might eventually be limited
by iron overload, it is nonetheless remarkable for a
pharmacological agent as familiar, safe and inexpensive
as iron to offer promise for an entirely new indication,
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and further studies are warranted to determine whether
careful adjustment of iron balance has any place in the
management of hypoxic pulmonary hypertensive disease.
Perhaps most immediately, potential protective effects of
iron loading should be investigated for HAPE, which
afﬂicts non-acclimatized individuals ascending rapidly to
highaltitude.HAPEisassociatedwithanexcessivehypoxic
pulmonaryvasoconstrictiveresponsethatischaracteristic
ofHAPE-susceptibleindividuals(Hackett&Roach,2001)
and that might be attenuated by parenteral iron, as was
observed in this study.
O u rh y p o t h e s i s–t h a ta l t e r a t i o n si ni r o na v a i l a b i l i t y
affect the pulmonary vascular response to hypoxia – was
predicated on the known effects of iron manipulation on
HIF hydroxylation, and on evidence implicating HIF in
pulmonaryvascularresponsesinvivo.Thepositi v er es ults
we obtained would therefore imply that iron availability
indeed modiﬁes HIF hydroxylation in the pulmonary
circulation,whichappearstobelimitedbynormalphysio-
logical levels of iron. This is difﬁcult to prove formally as
thereisnomeansofdirectlyquantifyingHIFinthehuman
lung,andperipheralconcentrationsofHIF-regulatedgene
products such as erythropoietin do not necessarily reﬂect
HIF activity in the pulmonary vasculature. However, it is
of interest that iron chelation and iron supplementation
emulated the pulmonary vascular manifestations of up-
and down-regulation of HIF that are seen in Chuvash
polycythaemia (Smith et al. 2006) and HIF+/− mice (Yu
et al. 1999; Brusselmans et al. 2003), respectively.
An alternative explanation for our ﬁndings is that the
responses were due to some novel iron-dependent oxygen
sensor, possibly another member of the iron-dependent
dioxygenase enzyme family. Up to 40 such enzymes may
sense changes in iron and oxygen availability and might
mediate HIF-independent responses to these stimuli
(Elkins et al. 2003; Elvidge et al. 2006; Ratcliffe, 2006;
Ozer & Bruick, 2007). A further theoretical explanation
is that iron availability inﬂuenced pulmonary vascular
tone through the formation of oxygen free radicals.
However, the precise role of reactive oxygen species
in hypoxic pulmonary vasoconstriction is controversial
(Aaronson et al. 2006). Furthermore, it is likely that any
such hypothetical effect would be rapid, yet PASP and
 PASPwerenormalwhenmeasuredshortlyaftertheiron
infusion. Nevertheless, involvement of reactive oxygen
species cannot be excluded as the time course of the
observed effects could reﬂect, for example, that of iron
uptake into pulmonary arterial myocytes.
We conclude that iron availability modiﬁes pulmonary
arterial pressures and pulmonary vasoconstrictive
responses to acute and sustained hypoxia, and suggest
thatthisinteractionmayderivefromrespectiveinhibition
and potentiation of HIF hydroxylation in the lung. Until
further evidence is forthcoming it may be prudent to
avoid iron deﬁciency in hypoxic patients with end-stage
pulmonary hypertension, and in HAPE-susceptible
individuals returning to high altitude. Further research
should investigate the link between iron status and
pulmonary arterial pressure, and explore the therapeutic
potential of manipulating iron and HIF in hypoxic
pulmonary hypertensive disease.
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